SNTI shows severe financial deterioration with stockholders' equity plummeting 78% and cash reserves declining 66% while losses increased.
The company faces a potential liquidity crisis with cash dropping from $48.3M to $16.4M and stockholders' equity falling to just $5.6M, raising serious going concern questions. Despite the financial deterioration, the company appears to be advancing its SENTI-202 program with reported clinical data from 20 AML patients, though this progress hasn't translated to improved financial performance.
SNTI's financial position has deteriorated dramatically across all key metrics, with stockholders' equity falling 78% to $5.6M and cash reserves declining 66% to $16.4M, while total assets dropped nearly 48%. Operating losses worsened by 12.7% to $68.8M and net losses increased 16.4% to $61.4M, indicating accelerating cash burn. The only positive was a modest 29.6% increase in accounts receivable, but this is insignificant compared to the overall financial distress that suggests potential funding needs or going concern issues.
Capital expenditure jumped 653.8% — major investment cycle underway; assess returns on deployment.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Cash declined 66% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 60.5% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 47.6% — asset sales, write-downs, or balance sheet optimization underway.
Receivables grew 29.6% — monitor days sales outstanding for collection efficiency.
Net income declined 16.4% — review whether driven by operations, interest costs, or non-recurring items.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →